# Sermorelin References: The Cited Research and Sources

> Sermorelin references — the full list of peer-reviewed studies, editorials, and reviews cited across this digest, with journals, years, DOIs, and PubMed links for every claim.

Every study cited across this sermorelin digest, with journal, year, DOI, and PubMed link — so each claim can be checked at the source.

## How to read this list

Every numbered citation below corresponds to a bracketed marker — [1], [2], and so on — placed beside the claim it supports throughout this site. The list mixes primary human trials, non-human-primate safety work, pharmacokinetic studies, editorials, and a recent review, reflecting the spread of the sermorelin and GHRH(1-29) literature. Where a study used a stabilized analog (such as tesamorelin or an [Nle27] form) rather than native sermorelin, the body text says so; the citation here records the source as published. PubMed identifiers and DOIs are provided for direct verification.

## References

[1] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[2] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/
[3] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[4] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[5] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[6] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. (SMART trial, NCT00257712.) https://pubmed.ncbi.nlm.nih.gov/22869065/
[7] Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82:1472-9. https://pubmed.ncbi.nlm.nih.gov/9141536/
[8] Lanes R, Carrillo E. Long-term therapy with a single daily subcutaneous dose of growth hormone releasing hormone (1-29) in prepubertal growth hormone deficient children. Venezuelan Collaborative Study Group. J Pediatr Endocrinol. 1994;7:303-8. https://pubmed.ncbi.nlm.nih.gov/7735367/
[9] Mowles TF, Stricker P, Felix AM, et al. Effect of human growth hormone-releasing factor and a potent analog on antibody formation in African green monkeys. Horm Metab Res. 1991;23:530-4. https://pubmed.ncbi.nlm.nih.gov/1816063/
[10] Vance ML, Evans WS, Kaiser DL, et al. The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men: dose-response relationships. Clin Pharmacol Ther. 1986;40:627-33. https://pubmed.ncbi.nlm.nih.gov/3096623/
[11] Gelander L, Lindstedt G, Selstam G, et al. Effects of acute intravenous injection of two growth hormone-releasing hormones (GHRH 1-40 and 1-29) on serum growth hormone and other pituitary hormones in short children with pulsatile growth hormone secretion. Horm Res. 1989;31:213-20. https://pubmed.ncbi.nlm.nih.gov/2515143/
[12] Bagno L, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(13):10846-10859. https://pubmed.ncbi.nlm.nih.gov/25797248/
[13] Thomas A, et al. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Anal Bioanal Chem. 2016;408(13):3457-3464. https://pubmed.ncbi.nlm.nih.gov/26879649/
[14] Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. https://pubmed.ncbi.nlm.nih.gov/9005976/
[15] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. (Review.) https://pubmed.ncbi.nlm.nih.gov/39537825/

---

A scroll-read digest of the sermorelin literature, marginal notes and all — the record set down where the data stop, not a clinic, a prescription, or a counter.